Aptevo Therapeutics (NASDAQ:APVO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a report published on Saturday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Roth Mkm dropped their target price on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, September 23rd.

Aptevo Therapeutics Price Performance

NASDAQ:APVO opened at $0.31 on Friday. The business has a 50 day simple moving average of $0.22 and a 200-day simple moving average of $0.41. Aptevo Therapeutics has a 1 year low of $0.14 and a 1 year high of $10.80.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC bought a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned 18.36% of Aptevo Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.